Posted by Michael Wonder on 29 Sep 2020
BridgeBio Pharma and affiliate Origin Biosciences announces FDA acceptance of its new drug application for fosdenopterin for the treatment of MoCD type A
29 September 2020 - Application accepted under priority review designation with breakthrough therapy designation and rare paediatric disease designation previously granted.
BridgeBio Pharma and affiliate Origin Biosciences today announced the US FDA has accepted its new drug application for fosdenopterin (previously BBP-870/ORGN001), a cyclic pyranopterin monophosphate substrate replacement therapy, for the treatment of patients with molybdenum cofactor deficiency type A.
This is BridgeBio’s first new drug application acceptance.
